The CANTOS trial: Implications for the management of patients with residual risk
Also as CME accredited e-learning10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.
Video navigation menu
- hsCRP as a predictor of future CV events 02:13
- Pathways of disease: from CRP to IL-6 to IL-1 03:41
- CANTOS trial with canakinumab: design and primary CV outcomes 05:07
- Does a reduction in inflammation result in a decrease in CV death/all-cause mortality? 10:35
- Inhibition of the pulmonary inflammasome - reduced risk of incident lung cancer 12:27
- Individualized treatment based on residual cholesterol risk or residual inflammatory risk 13:17
This educational video is part of a series of Inflammation videos that are aimed to provide guidance and perspectives on the implications of addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Professor Paul Ridker, MD is Eugene Braunwald Professor of Medicine, Harvard Medical School; Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, MA, USA
Funding to produce this educational video was provided by an unrestricted educational grant from Novartis.
This is available as accredited online CME for members. Click the button below to enroll:Enroll